CD63 CRISPR/Cas9 KO Plasmid (m): sc-419564
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD63 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CD63 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD63 Antibody (MX-49.129.5): sc-5275
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD63 CRISPR/Cas9 KO Plasmid (m) | sc-419564 | 20 µg | $397.00 |
Overview
Cd63 encodes CD63, a tetraspanin enriched on late endosomes, lysosomes, and extracellular vesicles where it organizes tetraspanin-enriched microdomains and coordinates membrane protein trafficking. CD63 participates in endosomal maturation, multivesicular body biogenesis, exosome cargo sorting, and regulation of receptor turnover, influencing processes such as cell adhesion, migration, and immune cell signaling. Through interactions with integrins and other tetraspanins, CD63 impacts vesicular transport pathways that shape antigen presentation and intercellular communication. Altered CD63 expression or localization is frequently used as a readout in cancer biology, inflammation, and infectious disease models due to its close association with vesicle dynamics and tumor microenvironment signaling.
CD63 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Cd63 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Cd63 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Cd63 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CD63 protein expression.
This CRISPR knockout system enables efficient generation of Cd63-deficient cell models for investigation of CD63 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Cd63 exon(s) critical for CD63 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Cd63 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CD63 CRISPR/Cas9 KO Plasmid (m) and CD63 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Cd63 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CD63 HDR Plasmid (m) and CD63 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Cd63 homology arms to support homology-directed repair at defined Cd63 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.